Metoprolol Succinat Ratiopharm (Metoprolol Succinate)

Metoprolol succinate selectively antagonises β1‑adrenergic receptors located primarily in cardiac tissue. By blocking these receptors, the drug diminishes the effects of circulating catecholamines, leading to a slower heart rate, reduced contractile force, and decreased renin release. The overall result is lower cardiac output and reduced arterial pressure.

The dosage of metoprolol succinate is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Typical starting doses may differ for hypertension, angina, or heart failure, and the dose is often titrated upward to achieve therapeutic goals while monitoring for side effects.

Safety data for metoprolol succinate in pregnancy are limited, and the drug should only be used when the potential benefits justify the potential risks to the fetus. Likewise, it is excreted in breast milk; therefore, breastfeeding mothers should discuss risks and alternatives with their healthcare provider before continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metoprolol succinate is a β1‑selective blocker with a prolonged‑release formulation, offering once‑daily dosing and steady plasma levels. Compared with non‑selective agents such as propranolol, it has a lower risk of bronchospasm in patients with reactive airway disease. Its long‑acting profile may improve adherence relative to short‑acting β‑blockers that require multiple daily doses.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed. Do not store in the bathroom or near heat sources, and keep out of reach of children.

Metoprolol Succinat Ratiopharm is taken orally, usually once daily, with or without food as directed by the prescriber. The extended‑release tablet should be swallowed whole; crushing, chewing, or splitting the tablet can alter the release profile and should be avoided unless specifically instructed by a healthcare professional.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with asthma or COPD, and worsening heart‑failure symptoms. Patients should be educated to report symptoms such as fainting, unusually slow heartbeat, difficulty breathing, or sudden swelling of the legs or ankles promptly.

Metoprolol Succinat Ratiopharm is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, in those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals experiencing cardiogenic shock or overt heart failure decompensation.